Neuralink, Elon Musk’s brain implant company, says it has permission to test device in people | CBC News

Elon Musk’s brain implant company, Neuralink, says it’s gotten permission from U.S. regulators to begin testing its device in people.

The company made the announcement on Twitter Thursday evening but has provided no details about a potential study, which was not listed on the U.S. government database of clinical trials.

Officials with the Food and Drug Administration (FDA) wouldn’t confirm or deny whether it had granted the approval, but press officer Carly Kempler said in an email that the agency “acknowledges and understands” that Musk’s company made the announcement.

Neuralink is one of many groups working on linking the nervous system to computers, efforts aimed at helping treat brain disorders, overcoming brain injuries and other applications.

Earlier this week, for example, researchers in Switzerland published research in the journal Nature describing an implant that restores communication between the brain and spinal cord to help a man with paralysis to stand and walk naturally. There are more than 30 brain or spine computer interface trials underway, according to clinicaltrials.gov.

Neuralink considered an ‘investigational device’

Musk — who also owns Twitter and is the CEO of Tesla and SpaceX — said last December that his team was in the process of asking regulators to allow them to test the Neuralink device.

The device is about the size of a large coin and is designed to be implanted in the skull, with ultra-thin wires going directly into the brain.

Musk has said the first two applications in people would be to attempt to restore vision and try to help people with little or no ability to operate their muscles rapidly use digital devices. He also said he envisions that signals from the brain could be bridged to Neuralink devices in the spinal cord for someone with a broken neck.

After Musk made a presentation late last year about the device, Rajesh Rao, co-director of the Center for Neurotechnology at the University of Washington, said he doesn’t think Neuralink is ahead of other teams in terms of brain-computer interface achievements, but is “quite ahead” in terms of the hardware in the devices.

It’s unclear how well this device or similar interfaces will ultimately work, or how safe they might be. Neuralink’s interface is considered an “investigational device” at this point, and clinical trials are designed to collect data on safety and effectiveness.

In its tweet this week, Neuralink said that it is not yet recruiting participants for the study and will provide more information soon.